Joanna Peng

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

David S. Hong, Michael A. Postow, Bartosz Chmielowski et al. · Clinical Cancer Research · 2023 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus

Barbara Sullivan, Wayne Tsuji, Alan Kivitz et al. · Lupus Science & Medicine · 2016 · 73 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Craig H. Moskowitz, Michelle A. Fanale, Bijal Shah et al. · Blood · 2015 · 48 citations

Veterinary Medicine, Clinical Sciences, Oncology +14

Anti-LG3 Antibodies Aggravate Renal Ischemia–Reperfusion Injury and Long-Term Renal Allograft Dysfunction

Bing Yang, Mélanie Dieudé, Katia Hamelin et al. · American Journal of Transplantation · 2016 · 46 citations · Full text

Life Sciences, Immunology, Surgery +17

Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus–Coinfected Subjects With Hepatic Impairment

Joanna Peng, Federico Pulido, Sonja J. Causemaker et al. · The Journal of Clinical Pharmacology · 2006 · 45 citations

Pharmacy, Pharmacokinetics, Pharmacology +15